July 21 (Reuters) - GlaxoSmithKline plc: * GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination Source text for Eikon: Further company ...
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback